An article in January's American Journal of Psychiatry weighs the relative risk of mortality associated with various antipsychotics and mood stabilizers used in the treatment of...
A partnership designed to decrease antipsychotic use in elderly patients may have led to increased use of medications with even worse risk/benefit profiles.
New evidence suggests that lithium, commonly prescribed for bipolar disorder, can increase the risk of chronic kidney disease.
The use by mothers of any of four major classes of psychiatric medications during pregnancy significantly raises the risk that their babies will be born with low birth weights and will need to be hospitalized.
Common psychotropic medications may be contributing to the higher rates of physical illnesses and mortality in people diagnosed with mental illnesses.
A new study, published in the Journal of Clinical Psychiatry, investigates the effects of anticholinergic medications, such as antidepressants and antipsychotics, on cognition in older adults diagnosed with schizophrenia.
Between 2,150 and 4,100 children suffered from severe malformations connected to valproate prescription.
New research published in the July issue of The Journal of Clinical Psychiatry found that the use of mood stabilizers, antipsychotics, antidepressants, and hypnotics during pregnancy is associated with increased health risks to the infant.
A third of patients who have taken the common psychiatric medication lithium for over ten years have developed "chronic renal failure" from the drug.
Lithium appears to reduce libido and sexual function, and more research into the problem is needed.
Dutch researchers write in the Journal of Clinical Psychopharmacology that, in a prospective study of 7415 persons with diagnoses of schizophrenia, use of a first-generation...
A review of the scientific literature for withdrawal from mood stabilizers: mechanism of action, animal studies, withdrawal symptoms, discontinuation success rates, and relapse rates related to tapering speeds.
New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”
A trial in veterans who had survived a previous suicide attempt was stopped early because the drug was found to be no better than a placebo.
Researchers find that valproate decreases brain volume in a region associated with emotion processing across all participants.